glp 1 triple agonist Agonism Based Therapies for Obesity Retatrutide is a “triple agonist”
Description
"Next-generation incretin-based therapies: exploring multi-receptor agonism in metabolic disease." Journal of Endocrinology
Healthcare providers sometimes modify standard schedules based on individual response
Finally, the expanded indication landscape suggests that the GLP-1 platform will increasingly compete not just within obesity, but across MASH, cardiovascular protection, and potentially other metabolic conditions
Recent advances in understanding GLP-1R (glucagon-like peptide-1 receptor) function
GLP-1 medications like Ozempic, Wegovy, Zepbound, and Mounjaro are being hailed as breakthrough treatments, reshaping how Americans think about managing weight and metabolic health
However, they significantly change health markers like blood sugar and cholesterol, which will be visible on medical blood work
